MS Trust Education

MP calls for abolition of the MS drugs risk-sharing scheme

Mon, 8 Feb 2010 00:00:00 +0000

The Risk-sharing Scheme, the mechanism that makes disease modifying drugs for MS available on the NHS, was debated in Parliament on 2 February.

Exciting new exercise resource launched for people with MS

Mon, 1 Feb 2010 00:00:00 +0000

Following the success of the book Exercises for people with MS, the MS Trust has launched a new set of web pages full of exercises for people with MS.

More oral MS drug research results published

Tue, 26 Jan 2010 00:00:00 +0000

Research published in the New England Journal of Medicine (NEJM) suggests that the oral drug cladribine reduces relapse rates and disease progression in people with relapsing remitting MS.

Tysabri labelling changes recommended

Fri, 22 Jan 2010 00:00:00 +0000

The European Medicines Agency has recommended new measures for dealing with the risks associated with the drug natalizumab (Tysabri).

Oral MS drug research results published

Thu, 21 Jan 2010 00:00:00 +0000

Research published online today in the New England Journal of Medicine (NEJM) suggests the new oral drug fingolimod may be more effective than current disease modifying drugs for MS.

Revised ABN guidelines published

Wed, 23 Dec 2009 00:00:00 +0000

At long last the new Association of British Neurologists (ABN) revised (2009) guidelines for prescribing disease modifying drugs in multiple sclerosis have been published.

MS Trust comment on the publication of Risk-sharing Scheme for MS data

Wed, 2 Dec 2009 00:00:00 +0000

The main objective of the Risk-sharing Scheme has always been to help people with MS. The Scheme is a unique initiative led by the Department of Health in conjunction with the Association of British Neurologists, the pharmaceutical industry, the MS Trust and the MS Society to give access to disease modifying drugs through the NHS. It has acted as the catalyst for the greatest improvement in MS services ever, and has thus brought tangible benefits to all people with MS across the UK.

Best practice treatment recommendations for Tysabri published

Tue, 1 Dec 2009 00:00:00 +0000

A supplement in the current issue of the medical journal Multiple Sclerosis features a paper outlining best practice recommendations for the selection and management of people with MS receiving natalizumab (therapy).

MS Trust comments on CCSVI research

Wed, 25 Nov 2009 00:00:00 +0000

CCSVI research is being widely reported in the media at present.

'Quality and MS care' - MS Trust conference 2009

Mon, 23 Nov 2009 00:00:00 +0000

'Quality and MS care' was the theme of the MS Trust's 13th Annual Conference which took place at Chesford Grange, Warwickshire. Quality is a term that also applies to the wide range of presentations and seminars that took place over the course of the three day conference.